HANSA BIOPHARMA

Investor Presentation

Økonomisk Ugebrev Life Science Conference
Copenhagen, October 26, 2022

Klaus Sindahl
Head of Investor Relations

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Hansa Biopharma today

Successful track record...
Strong momentum...
Promising future...

A validated technology

VALIDATION ACROSS THREE AREAS

- Approval in kidney transplantations
- Proof of concept in autoimmune diseases
- Partnerships to explore gene therapy

Idefirix® is our first approved drug in Europe*

EUROPE KIDNEY TRANSPLANTS

For highly sensitized patients in Europe

Broad pipeline in transplantation and autoimmunity

PROGRAMS IN CLINICAL DEVELOPMENT

US kidney transplants
Anti-GBM
Guillain-Barré syndrome (GBS)
Antibody mediated kidney transplant rejection (AMR)

Established a high-performance organization

NEW COMPETENCIES ADDED

145 employees September 2022 (~3x in 3 years)

Highly qualified team with 20 years on average in life science

Purpose driven culture

With current cash position Hansa is financed through 2024

FINANCIALS

SEK 1.2bn in Cash and short term investments (USD ~120m) end of September 2022

SEK ~70m raised through NovaQuest financing transaction in July 2022

Created shareholder value and diversified our ownership base

MARKET CAPITALISATION (USD): ~300m

Listed on Nasdaq Stockholm
18,000 shareholders
Foreign ownership make up ~40% through leading international life science specialist funds

*Idefirix approved in EEA under conditional approval for kidney transplantation

**Actual patient has given consent to provide images

Many milestones achieved during the last 15 months



Imlifidase

A novel approach to eliminate pathogenic IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection

A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing by H1 2024

HANSA BIOPHARMA

Our Business model

Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications



Idefirix® (imlifidase) has received conditional approval in the European Union

Low complexity transplants ⟵ ⟶ Higher complexity transplants

~70% of patients[1,2]	15-20% of patients[1,2]	10-15% of patients[1,2]
Non or less sensitized (cPRA < 20%)	Moderately sensitized (20% < cPRA < 80%)	Highly sensitized (cPRA > 80%)
		Highly sensitized patients that are likely to be transplanted with a compatible donor
		Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs

Actual patient has given consent to provide images

Idefirix® is indicated for

desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.

The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients

Potential patients

idefirix® imlifidase

HANSA BIOPHARMA

[1] EDQM. (2020). International figures on donation and Transplantation 2019
[2] SRTR Database and individual assessments of allocation systems

The kidney transplantation landscape in Europe and the U.S.

Up to 15% of patients waiting for a new kidney are highly sensitized

Breakdown of the kidney transplant waitlist in U.S. and EU



~50,000 transplants done annually in the U.S. and Europe



*Reported to be impacted by the COVID-19 pandemic

Source: Global Observatory on Donation and Transplantation, http://www.transplant-observatory.org/

Source: The U.S. Department of Health and Human Services and .irodat.org

Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation

Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers

Illustrative



1 Build the foundation for Idefirix® in EU to become a new Standard of Care

- Commercialize in early-launch countries focusing on leading clinics and early adopters
- Secure Pricing and Reimbursement agreements
- Ensure clinical readiness and KOL engagement
- Implement new medical guidelines through ESOT
- Increase awareness on unmet need through KOL engagement, patient organizations and medical conferences
- Initiate post approval study in Europe to support full approval and establish long-term outcomes

"Low initial uptake and volatile growth"

Sales initially remain "low and volatile" between quarters during the initial launch years until early positive experiences are generated for Idefirix® to become a new SoC

2 Expanding internationally will lead to more accelerated growth mid term

- Leverage experience to scale Idefirix in Europe with early-launch centers and in the five largest markets after completing market access
- Launch in the U.S. following completion of the ConfIdeS study and FDA approval
- Expand to select markets and regions beyond core markets in EU and the U.S. through partnerships
- Full marketing authorization in Europe
- Support patient and organ access for highly sensitized patients

"More accelerated growth'

Expand broader and internationally

3 Potential label expansion will enable new growth pockets longer term

- Commercialize in AMR in kidney upon potential approval
- Potentially expand into living donor transplantation
- Potentially expand into other solid organ transplantations such as heart and lung pre- and post transplantation (AMR)

"Growth from pursuing new opportunities"

Potentially enable label expansions

HANSA BIOPHARMA

Positive reimbursement decisions received in Poland and Scotland for Idefirix® in highly sensitized kidney transplant patients

Market access has now been secured in nine European countries and procedures are ongoing in eight countries including Spain, Italy and Belgium



[1]Annual kidney transplantations 2019 (pre-Corona)
*Transplantation data is from Global Observatory on Donation and Transplantation, 2019
**Pricing & reimbursement obtained in France on an early access basis

First patient experiences with Idefirix in highly sensitized kidney patients post approval published

29-year-old woman transplanted with Idefirix at Erasmus Medical Center, Rotterdam

The woman has had kidney disease since childhood and has been dialysis dependent since 2016, after previously having had two transplantations where the organs were rejected.

Due to high levels of antibodies, it was virtually impossible for her to find a match through Eurotransplant but in March 2022, the 29-year-old was transplanted using Idefirix and is since doing well.

"She gained new perspective on a good life through transplantation" says nephrologist Annelies de Weerd

Link article in Amazing Erasmus from July 7, 2022

54-year-old man successfully transplanted at Vall d'Hebron, Barcelona after being on dialysis since 1984

The first patient transplanted in the post-approval study was a 54-year-old man who had been on dialysis since 1984. After two failed transplantation attempts in the 90s, the patient's immune system became sensitized, with very high antibody levels.

In May 2022, the patient received imlifidase treatment followed by a kidney transplant. After three months, he continues to be followed up on and does not require dialysis.

"This drug may open the door to transplantation for a group of highly sensitized individuals with virtually no option for a compatible transplant." says Dr. Francesc Moreso

Link article from Vall d'Hebron news forum August 25, 2022

Broad clinical pipeline in transplantation and auto-immune diseases

Candidate/ Project	Indication	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients[1,2]	EU: Additional agreements around reimbursement from H2'21
	US: Kidney transplantation in highly sensitized patients[1,2]	Completion of enrollment (64 patients) H2'22
	Anti-GBM antibody disease[3]	Pivotal Phase 3 study expected to commence in 2022 (50 patients)
	Antibody mediated kidney transplant rejection (AMR)	First data read-out H2 2022
	Guillain-Barré syndrome (GBS)	Completion of enrollment (30 patients) H2'22/H1'23
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)	Preclinical research
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)	Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)	Preclinical research
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology	Completion of GLP toxicology studies in 2022
EnzE	Cancer immunotherapy	Research



[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

Completed
Ongoing
Planned
Post approval study running in parallel with commercial launch

AMR Phase 2

AMR Phase 2 study

Aim of the study is test imlifidase ability to reduce the amount of donor specific antibodies in AMR patients post transplantation

CLINICALTRIALS.GOV ID

NCT03897205 (2019)

SUBJECTS

30 patients targeted (20 patients will be treated with imlifidase and 10 with Plasma exchange). Recruitment from 11 sites in the U.S., EU and Australia.

DOSES/FOLLOW UP TIME

1 dose of imlifidase (0.25 mg/kg) or 5-10 sessions of plasma exchange

MAIN OBJECTTIVES

- Imlifidase ability to reduce the amount of DSA in comparison with plasma exchange in patients who have an active AMR post transplantation
- Ensure safety for patients

STUDY DESIGN

- Randomized, open-label multi-center active control study, designed to evaluate the safety and efficacy of imlifidase in eliminating DSA in active AMR

STATUS

Completed enrollment awaiting first data read out H2 2022

Potential of using imlifidase vs. PLEX in AMR



U.S. ConfIdeS study: Completion of enrollment expected H2 2022; BLA submission expected 2024

U.S. trial design

64 highly sensitized kidney patients with the highest unmet medical need

- Patients with a cPRA score of ≥99.9% will be enrolled
- First patients enrolled at Columbia University, NYC
- 39 patients enrolled across ten sites October 19, 2022

1:1 Randomization

- When a donor organ becomes available and a positive crossmatch with the intended recipient indicates that the organ is not compatible, the patient will be randomized to either imlifidase or to a control arm, where patients either remain waitlisted for a match or receive experimental desensitization treatment*

Primary endpoint

- Mean estimated glomerular filtration rate (eGFR) “kidney function” at 12 months.
- For randomized patients who do not undergo transplantation, lose their graft or die before 12 months, eGFR will be set to zero, consistent with kidney failure

Secondary endpoint

- Patient survival at 12 months

Up to 15 leading transplantation centers in the U.S. will be engaged in the study

- Robert A. Montgomery, M.D. Professor of Surgery and Director, NYU Langone Transplant Institute, NYC is appointed to be the principal investigator

Timeline



*Experimental desensitization treatment can include any combination of plasma exchange (PLEX), intravenous IVIg, anti-CD20 antibody, and eculizumab. Link to the full protocol at ClincalTrials.gov

Total Revenue amounted to SEK 67m in the third quarter including SEK 23m in product sales

Revenue (Q/Q)



Net loss (Q/Q)



Operating cash flow (Q/Q)



Revenue (9M/9M)



Net loss (9M/9M)



Cash & short-term investments (Q/Q)



Upcoming milestones

Milestones subject to potential COVID-19 impact



Guidance assumes no persistent impact or further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.

Our unique antibody cleaving enzyme technology may have relevance across a range of indications

Targeting rare IgG mediated diseases

Anti-GBM paves the way for development in other autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin and blood disorders

IgG-cleaving enzymes to enable or even potentiate cancer therapy

- Allogenic stem cell (bone marrow) transplantation (HSCT)
- Enzyme-based antibody Enhancement (EnzE)



Expanding our commercial franchises

- Regulatory approval (conditional)
- Clinical development
- Partnership (preclinical development)
- Preclinical development
- Potential indications (currently not pursued)

Shaping a new standard for desensitization will help enable new indications in transplantations

- Antibody mediated rejection (AMR) in kidney transplantation
- Other transplantation types

Exploring opportunities in gene therapy

- Encouraging preclinical data published in Nature
- Validation through collaborations with Sarepta and AskBio
- Wide indication landscape beyond


HANSA
BIOPHARMA

Investor Relations

Contact

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com



Visit our new web site
www.hansabiopharma.com

Calendar and events

Oct 20, 2022	Redeye After Work presentation, Gothenburg
Oct 21, 2022	Redeye Lunch presentation, Stockholm
Oct 26, 2022	Økonomisk Ugebrev Life Science Conference, Copenhagen
Oct 27, 2022	HCA Capital Expert call on the commercial progress and launch strategy
Nov 22, 2022	Bryan Garnier KOL Expert call on kidney transplantation (virtual)
Nov 23, 2022	SEB Healthcare Seminar 2022, Stockholm
Nov 24, 2022	Redeye Life Science Day, Stockholm
Dec 1, 2022	Erik Penser Banks Temadag - Health Care, Stockholm
Dec 2, 2022	Geneva Corporate Access Midcap Event, Geneva
Dec 15, 2022	DNB Nordic Healthcare Conference, Oslo
Jan 9, 2023	JPM Week, San Francisco
Feb 2, 2023	Interim Report for January-December 2022
Mar 14, 2023	Carnegie Nordic Healthcare Seminar 2023
Mar 30, 2023	2022 Annual Report
April 20, 2023	Interim Report for January-March 2023
June 14, 2023	2023 Annual General Meeting
July 20, 2023	Half-year Report for January-June 2023
Oct 19, 2023	Interim Report for January-September 2023